The aim of the clinical trial is to investigate whether the use of a new multichannel endoscopic transanal access device (named UNI-VEC) is safe and effective in the resection of a rectal polyp or tumor that sits in the distal part of the colon (up to about 20 cm from the anal margin). This is the first study to test the device in humans, after proving its good performance in preclinical development (preclinical development has included functional laboratory tests and an animal trial).

Inclusion Criteria:

• All polyps included in the Paris Classification (Polypoid (0-I): Sessile type (Is), Pedunculated type (Ip), Non-polypoid (0-II, III): Raised type (IIa), Flat type (IIb), Depressed type (IIc), Excavated type (III))
• Lesions located from the anal margin to about 20 cm.
• Extent of at least 2 cm² (polyps 2 cm in diameter or areas of ERM or ESD 2 x 2 cm).
• Well or moderately differentiated tumours. T1: Tumours confined to the mucosa (Tis) and submucosa (T1).
• No positive lymph nodes.
• No lymphatic, vascular or perineural invasion.

Exclusion Criteria:

• Are considered vulnerable subjects.
• They suffer from hematological diseases with altered coagulation of their own or pharmacologically induced coagulation disorders (the use of acetylsalicylic acid (ASA) in doses of 150 mg/day is permitted).
• Have rectal lesions that lie above the pectineal line or extend into the anal canal.
• Local or distant metastasis.
• Have a score of more than 2 points on the Wexner faecal incontinence scale.

All IPD collected throughout the trial

Beginning 1 year after publication with no end date

A proposal that describes planned analyses must be submitted, and a data sharing agreement must be signed. The documents could be sent by email.